TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03449524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75mg CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150mg CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02779322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minigastric bypass
Description: The patient will be submitted to a minigastric bypass at the time of the operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: In this case a simplified conventional gastric bypass will be performed
Study: NCT02587377

Intervention type: OTHER
Group type: OTHER
Intervention: Non Standard of Care blood samples collection
Description: According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
Study: NCT00932828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Defatted peanut in flour form to be used as treatment for peanut allergy
Study: NCT04221776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group toilet training in daycare
Description: During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual toilet training at home
Description: Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
Study: NCT03218800

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Dose: 1g per day if creatinine clearance \> 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Dose: 1g per day if creatinine clearance \> 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes.
Study: NCT00814060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study: NCT01809639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard placebo
Study: NCT03288233

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath carbon monoxide measurement
Description: Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
Study: NCT04325841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine autologous anti-CD19 chimeric antigen receptor T cells
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
Study: NCT03675009

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Programming
Description: Green Cleaning educational programming to day care staff.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Programming
Description: Green Cleaning educational programming to day care staff.
Study: NCT00978757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine: 0.25 mg/kg, intravenously, one dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study: NCT02883257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
Study: NCT04228133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT)
Description: A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Bias Modification (ABM)
Description: A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
Study: NCT00845091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: moderate-intensity, low-impact, supervised, aerobic exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Healthy Education
Description: Educational topics related to heart health (e.g., nutrition, smoking, sleep)
Study: NCT01707407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg pomalidomide capsule administered orally once in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg pomalidomide capsule administered orally once in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: 50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11
Study: NCT02505399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Ticagrelor will be administered orally, according to the following scheme:~* 180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 90 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 90 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel will be administered orally, according to the following scheme:~* 300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 75 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 0 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).
Study: NCT01175941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: 10 mg NRL001 in a 2 g suppository, administered once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matched placebo - administered as a 2 g suppository, once daily for 7 days
Study: NCT01390259

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Open-Loop
Description: This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop
Description: In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
Study: NCT04385563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B211
Description: Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
Study: NCT04437121

Intervention type: OTHER
Intervention: Online Survey about Dietary and Lifestyle Habits
Description: An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections.
Study: NCT03665519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare milk
Description: The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid treatment will be given for 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid treatment will be given for 3 months.
Study: NCT02117557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Study: NCT01142804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group
Description: Walking programs with various levels of support will be administered to determine which one is most effective.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group
Description: Walking programs with various levels of support will be administered to determine which one is most effective.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group
Description: Walking programs with various levels of support will be administered to determine which one is most effective.
Study: NCT03069729

Intervention type: OTHER
Intervention: no intervention
Description: This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.

Intervention type: OTHER
Intervention: no intervention
Description: This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.

Intervention type: OTHER
Intervention: no intervention
Description: This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
Study: NCT03712085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal acupuncture
Description: Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham abdominal acupuncture
Description: Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
Study: NCT04122651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'Off the shelf' toric lens
Description: 'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Toric lens
Description: Fully targeted toric intraocular lens correction for corneal astigmatism
Study: NCT03147157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tacrolimus regimen guided by HLA matching rate
Description: required low,middle and high tacrolimus concentration in high,middle and low MR group respectively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tacrolimus regimen guided by HLA matching rate
Description: required low,middle and high tacrolimus concentration in high,middle and low MR group respectively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tacrolimus regimen guided by HLA matching rate
Description: required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
Study: NCT00685009

Intervention type: DRUG
Intervention: Estrogen hormone therapy
Description: Estrogen pill daily

Intervention type: DRUG
Intervention: Estrogen plus progesterone hormone therapy
Description: Estrogen plus progesterone hormone therapy pill (Prempro) daily

Intervention type: DRUG
Intervention: Placebo
Description: Placebo pill daily
Study: NCT03229694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracleer 125Mg Tablet
Description: Tracleer was administered orally at two hours before surgery and six hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally at two hour before surgery and six hours after surgery.
Study: NCT02270944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Vaccine
Description: Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBS Vaccine
Description: Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
Study: NCT03336593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine
Description: 1 dose of Trivalent Influenza Vaccine
Study: NCT03523598

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel + Normal Toothpaste
Description: * 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Gel + Potassium Nitrate Toothpaste
Description: * 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate Gel + Normal Toothpaste
Description: * 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes.
Study: NCT01552421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TV NOTES cholecystectomy
Description: Transvaginal NOTES cholecystectomy
Study: NCT01311284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope
Description: Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope
Description: Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope
Description: Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: intubate with the macintosh laryngoscope
Study: NCT04385563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.
Study: NCT01311284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath
Description: Intubate with McGrath device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq Nasotracheal
Description: intubate with Airtraq Nasotracheal
Study: NCT02603263

Intervention type: OTHER
Intervention: Social Norms Poster
Description: A poster containing a social norms message: Most people here choose to eat vegetables with their lunch
Study: NCT03880500

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Spinal Manipulative Therapy
Description: The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
Study: NCT00569894

Intervention type: BIOLOGICAL
Intervention: FLuMist
Description: One or two vaccinations with FluMist depending on prior vaccination status.